To identify factors that influence plasma levels and assess the prognostic value of lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in a prospective, population-based survey of the epidemiology and pathogenesis of atherosclerosis.
Introduction
Oxidative stress is a key mechanism through which atherosclerosis and cardiovascular disease (CVD) develops. It is mediated by reactive oxygen species that alter the fundamental properties of cholesterol, cholesteryl esters, and phospholipids on lipoproteins, as well as other proteins, to make them dysfunctional, immunogenic, and pro-atherogenic. 1, 2 Oxidative stress can be enhanced by non-enzymatic pathways, such as by copper and iron cations, as well as by enzymatic pathways, such as by lipoxygenases, myeloperoxidase, and NADPH oxidase. 3 These pro-oxidant pathways are balanced by anti-oxidant mechanisms, such as anti-oxidant vitamins (alpha-tocopherol and carotenoids) present within lipoproteins, and anti-oxidant enzymes, such as superoxide dismutase and glutathione peroxidase. 4, 5 Many of these enzymes and products of oxidation can be measured in the circulation, including oxidized low-density lipoprotein, oxidized phospholipids, isoprostanes, and myeloperoxidase, and have been shown to predict the presence of CVD and incident cardiovascular events (reviewed by Tsimikas 6 ).
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme with broad specificity in cleaving oxidized fatty acids at the sn-2 positions of oxidized phospholipids thereby generating lysophosphatidylcholine and free oxidized fatty acids. Based on studies in Lp-PLA2-deficient individuals and overexpression studies in animals, it was proposed that Lp-PLA2 has antiatherogenic properties. 7 However, studies in animals with
Lp-PLA2 inhibitors 8 and most clinical evaluations, 9 -19 but not all, 20 -22 involving plasma measurements of Lp-PLA2 mass or activity, suggest that elevated levels of Lp-PLA2 enhance cardiovascular risk.
The Bruneck study is a prospective, population-based survey on the epidemiology and pathogenesis of atherosclerosis. The cohort consists of men and women 45 -84 years old (1995 evaluation) and was followed for 10 years. The subjects are extremely well characterized in terms of demographic, vascular, coagulation, lipid and biochemical factors, and life-style parameters. 23 The
Bruneck cohort represents a unique opportunity to identify factors that predict new cardiovascular events in an unselected population. Therefore, the aim of this study was to assess the predictive value of Lp-PLA2 activity for incident CVD, vascular and non-vascular mortality and to identify potential determinants of Lp-PLA2 activity.
Methods
Baseline demographics, laboratory, and life-style measure of the study subjects
The study population was recruited in 1990 as a sex-and age-stratified random sample of all inhabitants of Bruneck, Italy (125 women and 125 men in the fifth to eighth decades each, n ¼ 1000). The current study focuses on the 1995 re-examination of 765 subjects and a 10-year follow-up period (1995 -2005) . 23 Detailed information about incident cardiovascular events was available in all of these subjects (100% follow-up). The study protocol was approved by the appropriate ethics committees and all study subjects gave their written informed consent before entering the study. All risk factors were assessed by validated standard procedures. Study methodology and laboratory methods for factors listed in Table 1 were previously described in detail 23, 24 and are summarized in the Supplementary material online. The metabolic syndrome was defined as having three out of five of the following parameters: waist circumference in men .102 cm (.40 in.) and women .88 cm (.35 in.), triglycerides 150 mg/dL, HDL cholesterol in men ,40 and women ,50 mg/dL, blood pressure 130/85 mm, and fasting glucose 110 mg/dL.
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Determination of lipoprotein-associated phospholipase A2 activity Lp-PLA2 activity was measured with a commercially available kit (Azwell Inc., Osaka, Japan) as previously described. 24 Reference normal values provided by the manufacturer are ,800 IU/L (mmol/min/L).
Assessment of future cardiovascular events
Assessment of non-cardiovascular death and future cardiovascular events in the Bruneck population was described previously 24 and detailed in the Supplementary material online. In brief, the primary analysis was comprised of composite CVD, which included all incident cases of cardiovascular death, myocardial infarction (WHO definition), ischaemic stroke, and transient ischaemic attack (TIA) (criteria of the National Survey of Stroke) (n ¼ 82 
Results
Baseline demographic, clinical, and laboratory characteristics of the study subjects
Baseline demographic, clinical, and laboratory characteristics of study subjects (all of Caucasian origin) are shown in Table 1 . Data are presented for subjects with (CVDþ) and without (CVD2) incident CVD over the 10-year follow-up period. Those with incident CVD had significantly higher levels of Lp-PLA2 activity (884 + 196 vs. 771 + 192 mmol/min/L, P , 0.001 for difference) and were more likely to be older, male, physically inactive, and had higher levels of systolic blood pressure, fasting glucose, C-reactive protein, homeostasis model of insulin resistance (HOMA-IR), microalbuminuria, fibrinogen, total cholesterol, LDL-C, apoB-100, OxPL/apoB, Lp(a), and lower levels of retinol and carotene (normalized for LDL-C) ( Table 1) . Lp-PLA2 activity was higher in men than in women (817 + 205 vs. 749 + 179 mmol/min/L, P , 0.001) and modestly increased with age (r ¼ 0.073, P ¼ 0.045). Influence of Lp-PLA2 activity on plasma level
Association of Lp-PLA2 activity with vascular, coagulation, lipid and lifestyle variables, and antioxidant levels
Distribution of Lp-PLA2 activity approximates a normal distribution. Level of Lp-PLA2 activity was strongly correlated with ferritin, HOMA-IR, total cholesterol, triglycerides, LDL-C, and apoB-100, and inversely with HDL-C and anti-oxidant levels ( Table 1 and Supplementary material online, Figure S1A ). Moreover, level of Lp-PLA2 activity steadily increased with an increasing number of components of the metabolic syndrome clustering in individuals (age-/sex-adjusted Lp-PLA2 activity in subjects with 0 to 5 components: 736, 755, 769, 837, 869, and 851 mmol/min/L; P , 0.001) (Supplementary material online, Figure S1B ). No association was noted with life-style variables including smoking, alcohol, diet, body mass index (BMI), and sports activity. In a multivariable stepwise linear regression analysis (forced entry of age and sex), LDL-C or apoB-100 and ferritin level emerged as highly significant, independent determinants of Lp-PLA2 activity (P , 0.001 each). The metabolic syndrome added significantly to the model composed of age, sex, LDL-C, and ferritin ( Table 2 ). In this model, metabolic syndrome could be substituted by the number of metabolic abnormalities clustering in individuals (P ¼ 0.028). When allowing for antioxidant levels (available in 390 subjects), retinol levels additionally showed an independent relation with Lp-PLA2 activity (P ¼ 0.002).
Relationship of Lp-PLA2 levels with cardiovascular disease and mortality
In Cox regression analysis, the risk of incident composite CVD gradually increased across tertile groups for Lp-PLA2 activity ( Table 3) . This finding applied to base models adjusted for age and sex [hazard ratio (HR) (95%CI) 1.7 (0.9-3.4) and 2.9 (1.6-5.5) for comparison between the middle and highest vs. lowest tertile group; P , 0.001 for trend], and to multivariable models [HR 1.6 (0.8 -3.2) and 2.2 (1.1-4.8), P ¼ 0.019 for trend]. Similar HR was noted for the extended composite CVD endpoints, which included revascularization and peripheral arterial disease, and for individual disease endpoints (stroke and TIA, myocardial infarction) ( Table 2 ). Cox models calculated for a 1-SD unit increment in Lp-PLA 2 activity showed similar and consistent results ( Table 3 , right columns). Additional adjustment for statins and other standard cardiovascular therapies had no influence on the results (data not shown). Interestingly, the findings extended to vascular mortality [HR 2.0 (0.8 -5.2) and 2.7 (1.1 -6.5) for comparison between the middle and highest vs. lowest tertile group; P ¼ 0.044 for trend] but not to non-CVD death [HR 0.9 (0.5 -1.4) and 0.9 (0.5 -1.6), P ¼ 0.56 for trend]. Cumulative hazard plots are depicted in Figure 1 .
Supplementary analysis using sextiles of Lp-PLA2 activity indicate a gradual increase in CVD risk (data not shown). When using orthogonal polynomials, the linear term was highly significant (P ¼ 0.001) with no evidence of additional non-linear components.
Lp-PLA2 activity and cardiovascular risk in subgroup analysis
Associations were consistent in subgroups, including men vs. women [HR per 1-SD unit increment in Lp-PLA2, 1.62 (1.28-2.06) in men and 1.28 (0.90-1.81) in women; interaction P ¼ 0.25], diabetics vs. non-diabetics, BMI 25 vs. BMI .25, no prior CVD vs. prior CVD, non-smokers vs. current/ex-smokers, and in subjects with different LDL-C, C-reactive protein, and Framingham Risk Score (FRS) (Figure 2 ). There was a non-significant trend towards a stronger association in groups with lower LDL-C. However, there was a significant interaction with Lp(a) level (Figure 2 ).
Added predictive ability of Lp-PLA2 as a risk marker for cardiovascular disease
Addition of Lp-PLA2 activity level to equations based on the Framingham risk function resulted in a modest increase in the area under the receiver-operating characteristic (ROC) curve (0.737 vs. 0.717, D 0.020, P ¼ 0.31) (Figure 3) , but a significant improvement in the likelihood function (D likelihood ratio Chi-square 10.2; P ¼ 0.001). P-values derived from the modified HosmerLemeshow calibration statistic (comparing observed and predicted risk using decile categories of predicted probabilities) amounted to 0.54 and 0.61 for the models not including and including Lp-PLA2 indicating a marginal gain in model calibration. The net reclassification improvement for 10-year risk categories ,10%, 10 -20%, and .20% was 9.5% (P ¼ 0.11). Among individuals with outcome events, the proportions of subjects reclassified to a higher and lower risk category were 19.5 and 4.9%, respectively. Corresponding proportions among individuals free of CVD during follow-up were 11.3 and 6.1%.
Discussion
This prospective epidemiological study of unselected subjects followed for 10 years confirms that increased baseline Lp-PLA2 activity is associated with increased risk of future cardiovascular events. Importantly, it documents several novel observations consistent with the specific pathophysiological role of Lp-PLA2 in atherogenesis: first, it demonstrates a significant relationship with vascular death but not with non-CVD mortality consistent with a specific effect on the vessel wall; second, it identifies plasma ferritin levels, a measure of body and macrophage iron content and a potent pro-oxidant, 26, 27 as a potential modulator of Lp-PAL2 activity; third, it demonstrates an inverse correlation between antioxidant levels (normalized to LDL-C) and HDL-C with Lp-PLA2 activity; fourth, it confirms a significant relationship of Lp-PLA2 with the metabolic syndrome (AHA-NHLBI criteria), the number of metabolic syndrome parameters and level of HOMA-IR. In total, these data support an integral role of Lp-PLA2 activity in lipid peroxidation and cardiovascular risk. The totality of published reports on Lp-PLA2, measured either as mass or activity, suggest that it is significantly related to future CVD with hazard ratios of 1.5 -2.0, but with a modest attenuation of risk following multivariable analysis. The current study, which adjusted for age, sex, previous CVD, systolic blood pressure, smoking, diabetes, ferritin, fibrinogen, LDL and HDL cholesterol, waist-to-hip ratio, alcohol consumption, social status, sports activity, HOMA-IR, lipoprotein(a), C-reactive protein, and urinary albumin, confirms a similar role of Lp-PLA2 in predicting CVD. Importantly, we also documented that baseline Lp-PLA2 activity was associated with vascular but not non-vascular death (Figure 1) . The relationship between Lp-PLA2 and CVD risk was noted in most subgroups tested, including patients in various tertile groups for LDL-C and hs-C-reactive protein, and different FRS estimates. These data are consistent with studies in subjects with sudden death or undergoing carotid endarterectomy that have reported prominent expression of Lp-PLA2 within the necrotic core and surrounding macrophages of vulnerable and ruptured plaques and apoptotic cells. 28, 29 Furthermore, a correlation of atheroma volume documented by IVUS with Lp-PLA2 mass measured in the coronary sinus has been documented. 30 These findings suggest that Lp-PLA2 is intimately associated with the transition of such plaques to clinical events. Like with most other novel markers of vascular risk, no significant global increase in model performance ( Figure 3) was observed upon addition of Lp-PLA2 activity to a standard prediction model (based on the Framingham risk function). The net reclassification improvement was 9.5% but fell short of significance. There is some promise, however, for a clinical utility in subgroups especially subjects at moderate risk or in combination with other novel risk markers. A large-scale meta-analysis is currently underway to resolve this issue.
The determinants of plasma Lp-PLA2 mass and activity levels are not fully known. In this study, variables primarily related to lipoproteins, oxidation, and insulin resistance were correlated with Table 3 Association between Lp-PLA 2 activity and cardiovascular disease risk in the Bruneck study cohort (1995 -2005) Squares and lines are hazard ratios (HRs) and 95% confidence intervals. HRs were derived from Cox models and calculated for Lp-PLA 2 activity tertile groups (left-hand columns) and for a 1-SD unit increase in Lp-PLA 2 activity (right-hand columns). Primary composite endpoint: stroke, TIA, myocardial infarction, and vascular death. In all analysis, only the first outcome event occurring in study participants was considered while potential further or recurrent events were censored. Influence of Lp-PLA2 activity on plasma level Lp-PLA2 activity. In particular, a positive association was noted between Lp-PLA2 activity and LDL-C, apoB-100, ferritin, and HOMA-IR, but an inverse association with HDL-C and anti-oxidant levels. Although a cause and effect relationship cannot be determined from this study, it does suggest that Lp-PLA2 activity may be influenced by the underlying atherogenic and pro-oxidant milieu. Interestingly, well-accepted risk factors such as hypertension, diabetes, and smoking and life-style behaviours all were not correlated with Lp-PLA2 activity.
There is compelling evidence that levels of LDL-C correlate with Lp-PLA2 mass and activity. Although it is known that Lp-PLA2 is released by inflammatory cells and then attaches itself to apoB-100 through a specific non-covalent interaction, the factors that mediate changes in Lp-PLA2 have not been determined. In most subjects, the majority of Lp-PLA2 mass is found on LDL-C and a relatively small amount (5%) is found on HDL. 31 Interestingly, lipoprotein(a) particles carry proportionally more Lp-PLA2 mass (1.5-fold) and activity (up to 7-fold) compared to equimolar amounts of LDL in the same subjects (reviewed by Tsimikas et al.
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). In fact, a recent study from the Bruneck population showed that subjects in the highest tertile of both Lp-PLA2 activity and of oxidized phospholipids on apolipoprotein B-100 particles (OxPL/apoB) have nearly double the risk of future cardiovascular events compared to subjects in the highest tertile of each factor individually. 24 This suggests that a pro-oxidant environment where both substrate (OxPL) and enzyme (Lp-PLA2) activity levels are elevated results in a higher risk compared to each factor alone. Additionally, lipid lowering drugs have differential effects on LDL-and HDL-associated Lp-PLA2 activity. For example, whereas ezetimibe, rosuvastatin, and fenofibrate all reduce non-HDL-associated Lp-PLA2 mass and activity, only fenofibrate increases HDL-associated Lp-PLA2 mass and activity. 33 These data suggest that additional information on the pathophysiological role of Lp-PLA2 may be obtained by evaluating both its interaction with individual lipoproteins and makes a strong rationale for further research in this area. This is the first study to document that ferritin levels positively correlate with Lp-PLA2 activity and that HDL-C and anti-oxidant levels are inversely associated. Additionally, this study confirms the strong association between Lp-PLA2 levels and the metabolic syndrome. 34, 35 Ferritin is the main intracellular storage protein of iron.
Heavy metal cations, such as iron and copper, are strong catalysts for oxidation of lipoproteins resulting in a large number of biological properties that could in principle make oxidized LDL proatherogenic. 36 Haem, an iron complex with protoporphyrin IX, is also a strong LDL-oxidizing agent, especially when activated by low concentrations of peroxides. Small amounts of haemoglobin are constantly leaking from damaged erythrocytes, particularly in the vascular regions with turbulent flow, such as vessel bifurcations and aortic curvatures. Haemoglobin-induced LDL oxidation has been suggested to significantly contribute to the increased levels of OxLDL found in the plasma of the patients on haemodialysis. 37 Prior studies have primarily focused on Lp-PLA2 mass, which is now clinically available as an adjunct to clinical risk prediction. 38 In this study, we measured Lp-PLA2 activity, which is only available as a research assay. It has not been established whether Lp-PLA2 mass or Lp-PLA2 activity provide similar, complementary, or independent information. In published studies where both mass and activity were measured, 15, 22, 35 only a modest correlation was noted between Lp-PLA2 mass and activity. Future studies will be important to ascertain the role of each measure, particularly with the current clinical trials of Lp-PLA2 inhibitors to reduce cardiovascular risk. 39 
Limitations
Although this is a prospective study with 10-year follow-up, the number of events was limited. However, the cohort is extremely well characterized with 100% ascertainment of follow-up. Many of the associations with Lp-PLA2 were modest in strength, although highly statistically significant. These observations need to be verified in future studies. Influence of Lp-PLA2 activity on plasma level
